ESPR Esperion Therapeutics Inc
Price (delayed)
$1.39
Market cap
$275.01M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$0.28
Enterprise value
$721.46M
Through scientific and clinical excellence, and a deep understanding of cholesterol biology, the experienced Lipid Management Team at Esperion is committed to developing new LDL-C lowering medicines that will make
Highlights
ESPR's revenue has surged by 186% year-on-year and by 12% since the previous quarter
Esperion Therapeutics's EPS has surged by 86% YoY and by 55% QoQ
The quick ratio has contracted by 29% from the previous quarter but it has grown by 8% YoY
The gross margin has grown by 26% YoY but it has contracted by 2.7% from the previous quarter
Esperion Therapeutics's debt has increased by 9% YoY and by 6% QoQ
Key stats
What are the main financial stats of ESPR
Market
Valuations
Earnings
Shares outstanding
197.85M
Market cap
$275.01M
Enterprise value
$721.46M
Price to earnings (P/E)
N/A
Price to book (P/B)
N/A
Price to sales (P/S)
0.78
EV/EBIT
96.12
EV/EBITDA
95.32
EV/Sales
2.17
Revenue
$332.31M
Gross profit
$263.71M
Operating income
$54.4M
Net income
-$51.75M
EBIT
$7.51M
EBITDA
$7.57M
Free cash flow
-$23.97M
Per share
Balance sheet
Liquidity
EPS
-$0.28
EPS diluted
-$0.28
Free cash flow per share
-$0.13
Book value per share
-$1.97
Revenue per share
$1.78
TBVPS
$1.84
Total assets
$343.82M
Total liabilities
$732.54M
Debt
$591.21M
Equity
-$388.72M
Working capital
$91.77M
Debt to equity
-1.52
Current ratio
1.37
Quick ratio
0.91
Net debt/EBITDA
58.98
Margins
Efficiency
Dividend
EBITDA margin
2.3%
Gross margin
79.4%
Net margin
-15.6%
Operating margin
16.4%
Return on assets
-15%
Return on equity
N/A
Return on invested capital
1.4%
Return on capital employed
7.7%
Return on sales
2.3%
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
ESPR stock price
How has the Esperion Therapeutics stock price performed over time
Intraday
-1.42%
1 week
-14.72%
1 month
-18.24%
1 year
-51.74%
YTD
-36.82%
QTD
-3.47%
Financial performance
How have Esperion Therapeutics's revenue and profit performed over time
Revenue
$332.31M
Gross profit
$263.71M
Operating income
$54.4M
Net income
-$51.75M
Gross margin
79.4%
Net margin
-15.6%
ESPR's operating margin has surged by 193% since the previous quarter and by 112% year-on-year
ESPR's revenue has surged by 186% year-on-year and by 12% since the previous quarter
The company's operating income has surged by 135% YoY
Esperion Therapeutics's net margin has surged by 91% YoY and by 47% QoQ
Growth
What is Esperion Therapeutics's growth rate over time
Valuation
What is Esperion Therapeutics stock price valuation
P/E
N/A
P/B
N/A
P/S
0.78
EV/EBIT
96.12
EV/EBITDA
95.32
EV/Sales
2.17
Esperion Therapeutics's EPS has surged by 86% YoY and by 55% QoQ
The equity has increased by 15% YoY but it has decreased by 5% QoQ
ESPR's revenue has surged by 186% year-on-year and by 12% since the previous quarter
The price to sales (P/S) is 77% lower than the 5-year quarterly average of 3.5 and 47% lower than the last 4 quarters average of 1.5
Efficiency
How efficient is Esperion Therapeutics business performance
The return on invested capital has surged by 126% since the previous quarter and by 105% year-on-year
Esperion Therapeutics's return on sales has surged by 123% QoQ and by 102% YoY
The return on assets has surged by 84% year-on-year and by 46% since the previous quarter
Dividends
What is ESPR's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for ESPR.
Financial health
How did Esperion Therapeutics financials performed over time
The total assets is 53% less than the total liabilities
The total assets has soared by 67% YoY and by 9% from the previous quarter
The quick ratio has contracted by 29% from the previous quarter but it has grown by 8% YoY
ESPR's debt to equity is down by 28% year-on-year
The equity has increased by 15% YoY but it has decreased by 5% QoQ
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise
specified. Data from 
and Sharadar.